Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $7.27B
• Dividend Yield: N/A
• Average Volume (3M): 1.28M
• Price to Earnings (P/E): 61.4
• Beta (1Y): 0.25
• Revenue Growth: 25.71%
• EPS Growth: 4.48%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 0.29
• Shares Outstanding: 105,371,730
• 10 Day Avg. Volume: 952,946
• 30 Day Avg. Volume: 1,277,160
• PEG Ratio: -69.13
• Price to Book (P/B): 11.30
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 40.59
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 2.67
• Enterprise Value/Gross Profit: 10.25
• Enterprise Value/Ebitda: 13.97
• 1Y Price Target: $134.50
• Price Target Upside: 94.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 73 Outperform
• Price Target: $75.00 ▲(8.70%Upside)

Corcept Therapeutics' strong financial performance underpins its overall score, highlighting robust revenue growth and a solid balance sheet. However, high valuation metrics and short-term technical indicators suggest caution. The earnings call offers a balanced view, with positive growth potential offset by operational challenges.

Positive Factors

Pipeline Strength

Upcoming events in 2H25 will continue to underscore the strength of the commercial and clinical pipeline.

Product Approval Potential

Relacorilant could potentially receive a positive decision with a broad label from the US regulatory agency based on strong safety and efficacy data.

Supply Chain Improvement

A second specialty pharmacy is expected to be fully operational soon, which could improve supply chain efficiency.

Negative Factors

Intellectual Property Uncertainty

The appellate court decision on Korlym IP is expected to be a stock-moving event, which adds uncertainty to the stock.

Revenue Guidance Downgrade

The company revised 2025 revenue guidance downwards by $50M due to ongoing supply chain issues.

Sales Weakness

1Q sales of Korlym are expected to be weak sequentially due to seasonal need for prior-authorization re-ups and a 4Q distribution hiccup.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sale of its flagship product, Korlym, which is used to treat patients with Cushing's syndrome. The company markets and sells Korlym directly in the United States, which constitutes the main source of its revenue. Additionally, Corcept invests in research and development to expand its portfolio, aiming to develop new applications for its proprietary cortisol modulating drugs in various therapeutic areas such as oncology and metabolic disorders. While Korlym sales are the primary revenue stream, successful clinical trials and subsequent approvals for new indications could enhance its earnings potential in the future. The company may also engage in partnerships or collaborations with other pharmaceutical firms to broaden its market reach and accelerate development timelines, although specific partnerships were not detailed.

Corcept Therapeutics Financial Statement Overview

Summary

Corcept Therapeutics displays a robust financial profile with strong revenue growth and profitability margins, supported by a solid balance sheet with minimal debt. However, a slight decrease in cash flow metrics is noted, though cash generation remains effective.

Income Statement

Corcept Therapeutics has demonstrated strong revenue growth, with a 70.6% increase from 2021 to 2024 and a TTM revenue of $685.45 million. The company's gross profit margin remains impressive at approximately 98% consistently over the periods. However, there was a slight decline in EBIT margin from 19.7% in 2024 to 16.2% in the TTM, indicating some pressure on operational efficiency. Net profit margin stayed robust at around 19.4% in the TTM, showing stable profitability.

Balance Sheet

The company's balance sheet is strong, with a low debt-to-equity ratio of 0.01 and a high equity ratio of 80.7% in the TTM. Stockholders’ equity has shown consistent growth, increasing from $375.81 million in 2021 to $683.29 million in the TTM. This indicates a solid financial foundation with minimal leverage and significant equity backing.

Cash Flow

Operating cash flow remains healthy, with a slight decrease from $198.07 million in 2024 to $179.44 million in the TTM. Free cash flow has also decreased but remains positive at $177.16 million in the TTM. The operating cash flow to net income ratio is strong, indicating effective cash conversion from earnings, although there's a decline in free cash flow compared to previous years.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	716.08M	675.04M	482.38M	401.86M	365.98M	353.87M
Gross Profit	704.42M	664.16M	475.89M	396.47M	360.70M	348.29M
EBITDA	103.37M	136.95M	108.32M	113.89M	127.95M	130.44M
Net Income	131.98M	139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet
Total Assets	801.72M	840.55M	621.52M	583.43M	423.76M	571.73M
Cash, Cash Equivalents and Short-Term Investments	342.23M	383.33M	368.22M	436.62M	335.81M	476.89M
Total Debt	6.61M	6.94M	151.00K	1.14M	526.00K	2.55M
Total Liabilities	165.93M	160.96M	114.81M	81.59M	47.95M	48.39M
Stockholders Equity	635.79M	679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow
Free Cash Flow	180.28M	195.90M	126.90M	119.91M	167.42M	150.73M
Operating Cash Flow	182.20M	198.07M	127.04M	120.32M	167.89M	151.97M
Investing Cash Flow	-41.44M	-177.60M	90.91M	-114.33M	136.13M	-119.26M
Financing Cash Flow	-168.39M	-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 69.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Neutral. The current price of 69 is below the 20-day moving average (MA) of 69.92, below the 50-day MA of 71.76, and above the 200-day MA of 63.51, indicating a neutral trend. The MACD of -0.93 indicates Positive momentum. The RSI at 46.73 is Neutral, neither overbought nor oversold. The STOCH value of 40.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HALO	78 Outperform	$7.27B	15.66	147.06%	―	25.65%	57.10%
TECH	75 Outperform	$8.60B	66.91	6.53%	0.58%	4.72%	-35.33%
CORT	73 Outperform	$7.27B	61.40	21.42%	―	25.71%	4.48%
MDGL	56 Neutral	$6.71B	―	-50.16%	―	―	21.83%
LEGN	56 Neutral	$7.14B	―	-20.01%	―	112.54%	54.30%
SRPT	54 Neutral	$1.56B	19.61	-23.61%	―	59.15%	-1881.09%
Sector *	51 Neutral	$7.37B	0.33	-68.94%	2.37%	16.27%	0.42%

Corcept Therapeutics Corporate Events

Corcept Therapeutics Reports Q2 2025 Financial Results

On July 31, 2025, Corcept Therapeutics announced its financial results for the second quarter of 2025, reporting a revenue increase to $194.4 million from $163.8 million in the same quarter of 2024. Despite a slight decrease in net income, the company highlighted significant clinical development milestones, including the publication of results from its CATALYST and ROSELLA studies and ongoing New Drug Applications for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Corcept’s advancements in clinical trials and strategic stock repurchases indicate a robust growth trajectory and potential leadership in cortisol modulation therapies.

The most recent analyst rating on (CORT) stock is a Buy with a $67.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics Submits New Drug Application to FDA

On July 14, 2025, Corcept Therapeutics announced the submission of a new drug application to the U.S. FDA for relacorilant, a selective cortisol modulator, to treat platinum-resistant ovarian cancer. This submission, based on positive Phase 3 ROSELLA and Phase 2 trial data, marks a significant milestone for Corcept, which now has two NDAs before the FDA. The trials showed that relacorilant, combined with nab-paclitaxel, improved progression-free and overall survival without increasing adverse events compared to nab-paclitaxel alone. The approval of relacorilant could provide a much-needed treatment option for patients with platinum-resistant ovarian cancer, a condition with limited current therapies.

The most recent analyst rating on (CORT) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics Holds Annual Stockholder Meeting

On June 10, 2025, Corcept Therapeutics held its annual meeting of stockholders, where key decisions included the election of nine directors, ratification of Ernst & Young LLP as the independent accounting firm for 2025, and approval of executive compensation. These decisions are significant for the company’s governance and operational oversight, impacting its strategic direction and stakeholder relations.

The most recent analyst rating on (CORT) stock is a Buy with a $115.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics Reports Q1 2025 Financial Results

On May 5, 2025, Corcept Therapeutics announced its financial results for the first quarter of 2025, reporting a revenue of $157.2 million, an increase from $146.8 million in the same period last year. Despite a record number of prescriptions, the company’s net income per share decreased due to initial fulfillment issues by its specialty pharmacy vendor. The company reiterated its 2025 revenue guidance of $900-$950 million. Corcept’s clinical development highlights include progress towards FDA approval for relacorilant in hypercortisolism and upcoming NDA submissions for relacorilant in platinum-resistant ovarian cancer. The company is also advancing studies in ALS and MASH, with significant findings from its DAZALS study showing improved survival rates for ALS patients on dazucorilant.